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BORTEZOMIB OR CARFILZOMIB FOR MULTIPLE MYELOMA PATIENTS 
RECENTLY RELAPSED OR REFRACTORY TO THEIR LAST COMBINATION 
REGIMEN CONTAINING EITHER BORTEZOMIB OR CARFILZOMIB 
ELI FOROUZAN 
 ABSTRACT  
Background: Multiple myeloma is a rare form of cancer that affects the proper 
function of plasma cells in the immune system. Patients experience symptoms 
ranging from bone pain to otherwise avoidable infections that can have negative 
effects on quality of life. Despite advances in multiple myeloma treatment leading 
to longer patient survival, it is still an incurable form of blood cancer. As a result, 
it is important for researchers to constantly investigate new avenues of treatment 
in order to delay disease progression. This study investigated whether the next 
generation proteasome inhibitor, ixazomib, could safely delay disease 
progression in patients who failed a combination regimen that included either the 
proteasome inhibitor bortezomib or carfilzomib.      
Methods: This study is a phase 1/2, 3+3 design, intra-patient, multicenter, open-
label, and non-randomized clinical trial that recruited patients that were 
previously on one of ten combination treatments containing the proteasome 
inhibitors bortezomib or carfilzomib. Patients must have shown progressive 
disease while on this treatment in order to qualify. They were given the same 
drugs and doses they were previously taking except that the proteasome inhibitor 
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was replaced with ixazomib. The safety and efficacy measurements were taken 
periodically to assess patients’ disease burden. To assess safety, adverse 
events (AEs) and serious adverse events (SAEs) were recorded, codified, and 
quantified for analysis. In addition, the maximum tolerated dose (MTS) of 
ixazomib for three regimens for which it was unknown was investigated through 
the analysis of dose limiting toxicities (DLTs). Clinical benefit rate (CBR) and 
overall response rate (ORR) using response data were also determined. Lastly, 
Kaplan-Meir statistical analysis was used to calculate the secondary efficacy 
endpoints such as progression free survival (PFS) using data collected 
throughout the trial. 
Results: Safety:  24.4% of patients experienced at least one ≥ Grade 3 serious 
adverse event, 33.3% experienced at least one ≥ Grade 3 adverse event, and 
two experienced dose limiting toxicities.  
Efficacy: ORR was 13.2% and the CRR was 18.4%. Median PFS was 2.1 
months, duration of response (DOR) was 2.0 months, and overall survival (OS) 
was 7.9 months. However, the MTD of ixazomib for the three regimens which it 
was unknown for was not found due to the nature of the data distribution.  
Conclusion: The results indicated that ixazomib is not an effective replacement 
for bortezomib or carfilzomib in combination treatments containing these drugs, 
which is apparent from low primary and secondary efficacy endpoints. However, 
due to a low occurrence of adverse events, serious adverse events, and dose 
limiting toxicities safety was confirmed. In addition, physicians should determine 
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the MTD on a case by case basis through individual dose escalations if ixazomib 
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 Multiple myeloma (MM) is a rare form of cancer that affects the plasma 
cells of the bone marrow and other sites of the body, severely hindering the 
immune system’s ability to function properly. It is characterized by an 
uncontrolled clonal expansion of dysfunctional plasma cells that overcrowd the 
nearby healthy plasma cells, disrupting their capacity to maintain the immune 
response necessary to fight infections.  The malignant plasma cells secrete a 
high amount of an abnormal immunoglobulin fragments such as monoclonal 
protein (M-protein) or free light chains (FLCs), which can cause many deleterious 
effects such as a hindered immune system, high blood viscosity, and renal 
damage (Mehta, 2015).  
Patients diagnosed with MM experience a multitude of symptoms that 
affect all aspects of everyday life. The most common ailments found in patients 
are skeletal problems such as bone pain, fractures, vertebral collapse, and 
hypercalcemia. This is due to the hyperactive effect MM has on osteoclasts and 
suppressive activity on osteoblasts, which can lead to bone lesions and 
weakness (Terpos et al., 2018). As a result of a weakened immune system, 
frequent infections are the leading cause of death in MM patients. High-risk 
patients often receive prophylactic treatment in order to prevent life-threatening 
infections from occurring (Blimark et al., 2015). Other symptoms include anemia, 
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fatigue, weakness, weight loss, nausea, vomiting, and more (Shephard et al., 
2015). 
Before developing active MM, patients undergo two other disease stages 
first. The first stage, called monoclonal gammopathy of undetermined 
significance (MGUS) is considered a benign condition and the most common 
plasma cell disorder. Patients are characterized as having a monoclonal 
immunoglobulin of 3.0 g/dL or less in serum, with a lack of anemia, bone lesions, 
hypercalcemia, and renal insufficiency (CRAB criteria). Then, patients progress 
to smoldering multiple myeloma (SMM), an asymptomatic disease with a higher 
serum immunoglobulin than 3.0 g/dL and/or bone marrow plasma cells greater 
than 10%. If plasma cell proliferation continues, SMM can turn into symptomatic 
MM within years (Kyle & Rajkumar, 2010).  
The International Staging System (ISS) is the most common method of 
classifying MM. It uses levels of serum albumin and beta-2 microglobulin (β2-M) 
to classify progression in a patient. Stage I has a β2-M < 3.5 mg/L with a serum 
albumin of 3.5 g/dL or more. Stage II either has a β2-M between 3.5 mg/L and 
5.5 mg/dL or albumin < 3.5 g/dL. Stage III has β2-M > 5.5 mg/L. This system is 
based on information collected from patients all across the globe and has mostly 
replaced the more cumbersome Durie-Salmon staging system, which requires 






 Around 32,000 adults in the United States are diagnosed with MM each 
year, making it the second most common blood cancer after non-Hodgkin 
lymphoma. The disease typically affects older individuals, with a median 
diagnosis between 66-70 years of age. Diagnosis before the age of 30 is 
extremely rare with a frequency of .02-0.3% for this age group. In addition, the 
incidence of MM in African Americans is higher than other groups, occurring up 
to triple the rate of white individuals (S. K. Kumar et al., 2017). MM also 
comprises of 1% of all cancers while occurring slightly more frequently in men 
than woman. Unfortunately, MM is not yet curable. Although significant strides 
have been made in MM treatment and patient life expectancy has substantially 
increased, it is estimated that 13,000 people will die in the United States each 




Currently, there are many classes of drugs available to treat MM patients. 
Frontline (the very first therapy MM patient is receiving post-diagnosis) therapy 
includes combinations of stem cell transplantation, immunomodulatory agents, 
proteasome inhibitors, alkylating agents, steroids and monoclonal antibodies. 
These combination therapies often include drugs such as bortezomib, 
lenalidomide, carfilzomib, pomalidomide, and more. However, patients almost 
always eventually develop resistance to these medications and disease starts to 
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progress into relapsed/refractory multiple myeloma (RRMM). Fortunately, as 
research has advanced, patients’ outcomes have improved, and medications are 
considerably more tolerable. In fact, survival rates have steadily increased since 
2000 due to new combination treatments (Fonseca et al., 2017).  Furthermore, 
median survival of patients has increased over the last 10 years, and has gone 
from 3–4 to 7–8 years (P. G. Richardson et al., 2015). 
Patients with RRMM are defined as individuals who have experienced 
minimal response (MR) or better, relapse, and then progress during salvage 
therapy (lines of therapy that followed frontline therapy) or within 60 days of their 
last therapy. These patients develop consecutively shorter response durations to 
treatments, which is a result of drug resistance and change in biological activity 
in cancerous cells ( Richardson et al., 2007). As a result, not only have new 
drugs within the frontline treatment classes been developed as salvage 
treatments, but also novel classes as well. Next-generation proteasome inhibitors 
(PIs) such as ixazomib, marizomib, and oprozomib are being researched as 
possible treatments for RRMM. In addition, drugs that target cell signaling 
pathways such as histone deacetylases and mTOR/PI3K/AKT inhibitors are also 
being developed, as well as newer monoclonal antibodies that bind cell surface 






Bortezomib and Carfilzomib 
Bortezomib (BTZ) is a first-in-class subcutaneously or intravenously 
administered PI that reversibly binds the β5 subunit of the 26S proteasome. The 
proteasome breaks apart ubiquitinated proteins that have been tagged for 
degradation by the cell. In addition, nuclear factor-κB (NF-κB) is a transcription 
factor that is held in the cytoplasm when it is associated with the inhibitor of 
kappa B (IκB). When IκB is targeted for degradation, free NF-κB travels to the 
nucleus where it stimulates the transcription of genes that block cell-death 
pathways, promote cell proliferation, and control the presence of cell adhesion 
molecules. Inhibition of the 26S proteasome causes IκB to be bound to and 
inhibit NF-κB, leading to anti-tumor activity (Rajappa, 2010). 
 As a result of proteasome inhibition, the cancerous cells also accumulate 
high levels of “junk” protein because of their tendency to generate a large amount 
of extra unnecessary proteins. This accumulation eventually causes the cells to 
undergo apoptosis. This mechanism is useful in treating MM and RRMM 
because rapidly dividing cancerous cells rely heavily on the protein degradation 
pathway, which is a weakness that can be exploited using PIs (Multiple Myeloma 
Research Foundation, 2018). BTZ has shown a great amount of synergistic 
activity in studies when combined with immunomodulatory agents and other drug 
classes such as alkylating agents (Nooka, Kastritis, Dimopoulos, & Lonial, 2015). 
However, side effects such as peripheral neuropathy (PN), along with 
gastrointestinal and blood/lymphatic disorders have been reported, especially in 
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elderly patient populations. (Castro, Hallack Neto, Atalla, & Ribeiro, 2016).  
Overall, BTZ has increased life expectancy as a single agent and in combination 
therapy for newly diagnosed patients, individuals with RRMM, and as a 
maintenance regimen (Mohan, Matin, & Davies, 2017).  
Another newly approved PI in RRMM patients is carfilzomib (CFZ), a 
second-generation epoxy-ketone that irreversibly inhibits the 20S and 26S 
proteasomes. It is usually administered via intravenous infusion as monotherapy 
or in combination with dexamethasone or lenalidomide plus dexamethasone 
(Perel, Bliss, & Thomas, 2016). CFZ has shown promising results as a treatment 
option for patients who are refractory to BTZ and has resulted in significant 
responses in RRMM patients. CFZ induces a higher level of proteasomal 
inhibition and a lower incidence of PN than BTZ. However, CFZ requires six 
infusion visits each cycle, significantly more than BTZ (Nooka, Kastritis, 
Dimopoulos, & Lonial, 2015). Unfortunately, CFZ has multiple side effects such 
as fatigue, nausea, diarrhea, anemia, thrombocytopenia and more. Recent 
studies have found significant cardiac risks associated with CFZ as well. Cardiac 
events such as hypertension, vascular problems, heart failure, arrhythmia, and 
myocardial infarction have been documented, raising safety concerns in recent 
years (Tjionas & Gupta, 2017). As a result, a new generation of PIs such as 






Ixazomib (IXZ) is a next generation PI approved in 2015 for patients who 
have received at least one prior line of therapy and   is administered orally instead 
of intravenously or subcutaneously (Buckler & Holle, 2016). Oral delivery is 
preferred over the other routes of administration because of the convenience and 
comfort provided to patients. IXZ is a boronate PI that also reversibly inhibits the 
chymotrypsin-like activity of the 20S proteasome. It has a shorter dissociation 
half-life and has shown greater tissue penetration than BTZ, while being 
metabolized by CYP enzymes (Park, Miller, Jun, Lee, & Kim, 2018).  
 




Studies have shown that IXZ has greater anti-tumor activity than BTZ and 
could slow MM cell growth without killing normal cells (Chauhan et al., 2011; 
Kupperman et al., 2010). One in vitro study conducted using human cell cultures 
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demonstrated that treatment of MM cells with IXZ resulted in concentration 
dependent drop in cell viability. Specifically, the cells were treated with various 
concentrations of IXZ for 48 hours and cell viability was measured using Annexin 
V+/P- apoptosis assay.  The results demonstrated significant decrease in cell 
viability due to apoptosis. As expected, proteasome inhibition by IXZ caused an 
accumulation of ubiquitinated proteins in a time- and dose-dependent manner. 
The researchers also examined IXZ efficacy in vivo using a human 
plasmacytoma MM xenograft mouse model. The results demonstrated that IXZ 
significantly inhibited MM cell growth while prolonging mouse survival (Chauhan 
et al., 2011). These results have been found typical in pre-clinical studies of IXZ.  
 
Clinical Experience 
 Results of a clinical trial investigating two administration schedules of IXZ 
in patients with RRMM at a weekly and biweekly dosing showed that patients 
receiving weekly MTD dosing of IXZ achieved partial response (PR).  The 
median DOR for these patients was 7.3 months. Patients enrolled showed 
adverse events (AE) such as thrombocytopenia, neutropenia, diarrhea, and 
fatigue when on the drug (Moreau, 2014).  Although other PIs such as CFZ have 
been associated with cardiac problems, PN, and renal toxicity, (Richardson et al., 
2017) few events were found to be attributable to IXZ. In addition, there was no 
increased risk of renal failure or thromboembolism associated with the drug. In 
regards to efficacy, another study found that the all-oral regimen of IXZ plus 
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lenalidomide-dexamethasone increased progression free survival by 35% when 
compared to lenalidomide-dexamethasone alone. These results were obtained 
with limited additional drug toxicity and no negative impact on patient quality of 
life (Richardson et al., 2017), while being well tolerated with infrequent PN 
(Kumar et al., 2013).  
 
Study Purpose  
IXZ’s profile reflecting better safety, more convenient rout of administration 
(oral) and improved efficacy in treating MM patients lead to the investigation of 
IXZ as a replacement therapy for BTZ or CFZ. The focus of this study is to 
determine whether IXZ is a suitable candidate to replace BTZ or CFZ in 
combination regimens for treatment of RRMM patients. 
 
Primary Objectives 
 The primary objectives of this study are to establish the safety and 
tolerability of IXZ as a replacement for BTZ or CFZ in combination regimens that 
include these drugs. Safety and tolerability was established by monitoring AEs 
graded using the Common Terminology Criteria for Adverse Events (CTCAE) 
(Appendix C). Since the maximum tolerated dose (MTD) of IXZ in the following 
three regimens is unknown, dose-determination became part of the primary 
objective. The MTD of IXZ in combination with BTZ+ cyclophosphamide + 
dexamethasone, BTZ + cyclophosphamide + ascorbic acid, and BTZ + pegylated 
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liposomal doxorubicin (PLD) + dexamethasone is unknown. MTD was to be 
determined by the number of dose limiting toxicities (DLT) that were presented 
during the standard phase 1 3+3 dose escalation design schema. In addition, the 
ORR (defined as complete response (CR) + very good partial response (VGPR) 
+ PR) and the CBR (defined as ORR + MR) will be used to assess efficacy 
according to the International Myeloma Working Group (IMWG) criteria. 
Secondary Objectives 
 The secondary objectives of this study were the following disease 
parameters: time to progression (TTP), progression-free survival, time to first 
response (TTR), duration of response, overall survival (OS), and incidence of PN 
among patients. These measurements are commonly used in MM clinical 
research to determine the effectiveness and duration of the treatment. They allow 
researchers to have a universal measurement standard with which to compare 





 This is a phase 1/2, 3+3 design, intra-patient, multicenter, open-label and 
non-randomized clinical trial. Participants were given IXZ in place of BTZ or CFZ 
with an alkylating agent (melphalan or cyclophosphamide), anthracycline (PLD), 
immunomodulatory imide drugs (IMiDs) (lenalidomide), ascorbic acid and/or a 
glucocorticosteroid (dexamethasone, prednisone or methylprednisolone) 
administered using the same schedule(s) and dose(s) of drugs as in the last PI-
containing regimen that the patient failed.  
 This study enrolled 45 patients who were refractory to a BTZ or CFZ 
containing combination regimen shown by PD while on treatment or relapsed 
within 8 weeks of their last dose. Patients also must have received at least four ≥ 
1.0 mg/m2 doses of bortezomib in no more than 28-days or at least six 27 mg/m2 
doses of carfilzomib in a 28-day cycle. To qualify for this study patients had to 
meet all of the above stated criteria. Patients who were refractory to their most 
recent PI-containing regimen were eligible regardless of when they received their 
regimen as long as these criteria were met, and they showed progressive MM at 




PI Containing Regimens 
 IXZ will be replacing CFZ and BTZ in the same PI-containing regimen the 
patients were previously on and have failed. The following ten regimens were 
evaluated:  
 
- BTZ+ melphalan + prednisone 
- BTZ + cyclophosphamide + dexamethasone 
- BTZ + cyclophosphamide + ascorbic acid 
- BTZ + PLD + dexamethasone 
- BTZ + dexamethasone 
- CFZ + dexamethasone 
- BTZ + lenalidomide + dexamethasone 
- CFZ + lenalidomide + dexamethasone 
- BTZ + pomalidomide + dexamethasone 
- CFZ + pomalidomide + dexamethasone 
 
Patients receiving combination regimens with the known IXZ MTD were 
directly enrolled into Phase 2 portion of this study using previously determined 





 The study consisted of: 1) a Screening period; 2) up to eight 28-day 
treatment cycles; 3) a maintenance period; 4) a final assessment to occur 28 
days after the end of the last treatment cycle; and 5) a follow-up period. 
Screening was done within 14 days before baseline, which is Day 1 of Cycle 1 
before drug is given. A signed and dated informed consent form was obtained 
prior to any screening procedures. After consent was received, screened 
subjects were assigned a six-digit permanent identification numbers. The first 
three digits were the designated clinical site number, and the last three digits 
were assigned by the sponsor Oncotherapeutics.  
 During the screening period, a medical history was recorded, as well as a 
physical exam that includes vital signs measurements, height, weight, Eastern 
Cooperative Oncology Group (ECOG) performance status, and 12 lead 
electrocardiogram. MM tests were conducted, including β2-M, serum FLC assay 
and ratio, serum and urine protein electrophoresis, quantification of serum 
immunoglobulins, urine/serum immunofixation and 24-hour total protein. Also, 
multiple gated acquisition scan or echocardiogram, postero-anterior and lateral 
chest radiographs, skeletal survey, and bone marrow aspirate and biopsy were 
performed within 28 days of baseline. Clinical laboratory tests including 
hematology, clinical chemistry (blood urea nitrogen, serum creatinine, uric acid, 
lactate dehydrogenase, total bilirubin, alkaline phosphatase, aspartate 
aminotransferase and alanine aminotransferase), electrolytes (potassium, 
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sodium, chloride and calcium), random glucose, total protein, amylase, albumin, 
and urinalysis will also be performed during the Screening period along with 
serum pregnancy tests for females of child bearing potential. 
 
Treatment Period 
 Patients were on the study for no more than 8 cycles. They were treated 
to a maximum response (lowest level of paraprotein) plus 1 additional cycle, 
while not exceeding 8 cycles, or complete 8 cycles of therapy without PD. 
Patients that showed stable disease (SD) or did not had maximal reduction in 
paraprotein levels after 8 cycles were taken off the combination regimen and 
were eligible for maintenance therapy. During treatment, patients had clinical 
laboratory tests performed to look for potential drug toxicity. Also, procedures 
monitoring for AEs, review of concomitant medications, and other support 
therapies (e.g. growth factors and transfusion), MM disease assessments, ECOG 
performance status, vital signs measurements and a physical examination were 
done at site visits. Patients were to remain on study until documentation of PD as 
described by the IMWG response criteria (Appendix A). Patients showing SD 
remained in the study.  
 
IXZ Treatment Schema 
 IXZ was given to patients orally at 4 mg on Days 1, 8, and 15 of a 28-day 
cycle to patients enrolled in seven regimens (BTZ+ melphalan + prednisone, BTZ 
	
 15 
+ dexamethasone, CFZ + dexamethasone, BTZ + lenalidomide + 
dexamethasone, BTZ + pomalidomide + dexamethasone, CFZ + lenalidomide + 
dexamethasone, and CFZ + pomalidomide + dexamethasone). Patients who 
were on these combination therapies received 4 mg of IXZ from the start of the 
trial for the length of study unless the onset of DLTs (Appendix B) required dose 
reduction. IXZ dose levels started at 4 mg, and then dropped to 3 mg, then to 2.3 
mg as DLTs occurred. If it was apparent the dose would need to be dropped 
lower than 2.3 mg, the patient was discontinued. Dose modification during any 
cycle followed the rules designated according to specific type of DLT and 
severity. 
 For patients previously treated with the other three regimens (BTZ+ 
cyclophosphamide + dexamethasone, BTZ + cyclophosphamide + ascorbic acid, 
and BTZ + PLD + dexamethasone) the MTD for IXZ was not known and intra-
patient dose escalation was performed to find the specific MTD for each 
combination. IXZ was given at 3 mg on Days 1, 8, and 15 of a 28-day cycle, 
followed by intra –patient dose escalation towards 4 mg in Cycle 2. All other 
agents in the combination therapy were administered at the same dose the 
patient was previously receiving. However, because of possible drug-drug 
interaction between IXZ and ascorbic acid, patients enrolled in that particular 
regimen were administered IXZ at the clinic in the morning and took ascorbic 
acid (vitamin C) in the evening, followed by cyclophosphamide. 
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 For the three combination therapies needing MTD determination, safety 
was the primary criteria for stopping treatment during the first two cycles. 
Patients needed to finish a minimum of a full cycle (28 days) without a DLT 
before moving on to the next cycle (during Cycles 1-2 only). If a DLT was seen in 
a patient, then treatment continued at one dose level lower. 
 
Table 1: Ixazomib dosing for bortezomib- or carfilzomib-containing regimens 
commonly found in the community 
Regimen Ixazomib dose(s) (mg) 
BTZ+ melphalan + prednisone 4 
BTZ + cyclophosphamide + dexamethasone 3→4  
BTZ + cyclophosphamide + ascorbic acid 3→4 
BTZ + PLD + dexamethasone 3→4 
BTZ + dexamethasone 4 
CFZ + dexamethasone 4 
BTZ + lenalidomide + dexamethasone 4 
BTZ + pomalidomide + dexamethasone 4 
CFZ + lenalidomide + dexamethasone 4 
CFZ + pomalidomide + dexamethasone 4 
 
Day 1 Assessments 
 Patients who met the inclusion/exclusion criteria during the Screening 
period continued to Day 1, Cycle 1 where baseline evaluations were conducted. 
Subjects had assessments done on Day 1 of each cycle such as: making sure 
subjects still meet inclusion/exclusion criteria (Day 1 Cycle 1 only), vital signs, 
calculation of body surface area, ECOG performance status and PN assessment. 
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In addition, samples were collected before the dispensing of drug, which looked 
at: hematology (hematocrit, hemoglobin, RBC count, WBC count, with 
differential, platelet count), serum chemistry (sodium, potassium, chloride, 
calcium, glucose, blood urea nitrogen, serum creatinine, total bilirubin, alkaline 
phosphatase, total protein, albumin, aspartate aminotransferase, alanine 
aminotransferase) and serum β-hCG test for females of child bearing potential. 
Patients were informed about pregnancy precautions and fetal exposure risks. 
Finally, serum protein electrophoresis with quantification of immunoglobulins 
(Cycle 1 and 2 only), assessment of concomitant medications, assessment of 
AEs from the start of study through 28 days after last dose administration, 
assessment of response to treatment, and administration of study drug occurred. 
Patients were observed at the clinical site for a 1 hour after drug administration 
during Day 1 of each cycle.  
 
 
Day 8 Assessments 
 Before drug administration on Day 8 of cycle 1 only (unless otherwise 
noted), vital signs, physical exams, hematology and serum chemistry samples 
(including β-hCG test for females of childbearing potential), serum protein 
electrophoresis, assessment of concomitant medications, assessment of AEs, 




Day 15 Assessments 
 On Day 15 of Cycle 1 only (unless otherwise noted), vital signs, physical 
exam, hematology and serum chemistry samples, concomitant medication 
assessment, AE assessments and administration of study drug occurred.  
 
Assessments During Rest Period (Days 22-25, Cycles 1-8) 
 The results of the following laboratory assessments were needed to be 
available before Day 1 of the next cycle in order to observe disease response 
and if necessary adjust the patient’s study drug regimen: vital signs, complete 
physical examination,  hematology/serum chemistry/ β-hCG sample collection 
(Cycle 1 only), MM disease parameter assessments (such as serum protein 
electrophoresis, urine protein electrophoresis, serum FLC assay and ratio, serum 
β2-M), collection and review of patient diary (Cycles 2-8), concomitant 
medication and AE assessment.  
 
Maintenance Therapy 
Patients who finished their combination therapy without having PD or met 
criteria for discontinuation from the study based on achieving maximum response 
were eligible to undergo single-agent IXZ maintenance therapy. During 
maintenance, IXZ was given at the same dose and schedule that the patient was 
getting as part of the combination treatment. During this time, patients had MM 
disease assessments once a month on Day 22 of each maintenance cycle. In 
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addition, AE monitoring, concomitant medication review, support therapies, 
ECOG performance status, vital signs, and physical examination were conducted 
during maintenance therapy. Patients stayed on maintenance treatment until they 
showed PD as defined by the IMWG criteria or until toxicity developed. Patients 
showing SD stayed on maintenance therapy. IXZ was administered at home 
orally, while patients also kept a diary detailing the date/time of drug 
administration and any AEs experienced. Patients were instructed to bring their 
diary to each assessment visit along with the empty blister pack. 
 
Day 1 of Each Maintenance Cycle 
 On Day 1 of each maintenance cycle, several assessments were done: re-
review of inclusion/exclusion criteria (subject had to still meet all eligibility criteria 
as seen at the Screening period), vital signs, physical examination, assessment 
of concomitant medications, and assessment of AEs.  
 
Day 22 of Each Maintenance Cycle  
 On Day 22 of each maintenance cycle, vital signs, ECOG performance 
status, PN assessment, hematology and serum chemistry clinical laboratory 
evaluations, amylase assessment, β-hCG pregnancy test, MM disease 
parameter assessments, assessment of response to treatment, collection and 
review of patient diary, assessment of concomitant medications, and assessment 




 28 days after the final dose was administered, the patients completed a 
final assessment known as the End-of-Study visit. During this visit, numerous 
procedures were performed: a MM disease assessment, measurement of vital 
signs, a physical examination, assessment of AEs, a review of concomitant 
medications, assessment of ECOG performance status, hematology/clinical 
chemistry laboratory tests, and an assessment of response to treatment. Patients 
who left the study before completion of the eight 28-day cycle evaluation period 
had all End-of-Study treatment assessments at their final visit. After the End-of-
Study visit, patients were watched for PD and survival through clinic visits every 
3 months until a new therapy needed to be started or death intervened.  
 
Study Duration 
 The study had a duration of 24 months for enrollment and lasted 48 
months from beginning until the end of the study (including the maintenance 
period). Each treatment cycle was 28 days, and patients were treated to 
maximum response plus another additional cycle or a maximum of eight cycles. 
The lowest point in paraprotein levels was considered the maximum response.  
 
Efficacy Measurements  
 Efficacy measurements were done on the same day as the medications 
were taken, before the drugs were administered.  
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Serum Protein Electrophoresis with Quantification of Immunoglobulins and 
Immunofixation 
 Serum protein electrophoresis with quantification of immunoglobulins and 
immunofixation occurred during the Screening period and on Day 22 of every 
cycle. The gamma globulin region of the electrophoretic pattern is higher in 
patients with plasma cell tumors and can be used to measure tumor burden. 
Immunoelectrophoresis or immunofixation was required to truly prove that the 
spike in this region was monoclonal and that a single light and heavy chain type 
was present.  
 
Urine Protein Electrophoresis and Immunofixation 
 Urine protein electrophoresis and immunofixation was conducted on a 24-
hour urine specimen during the Screening period, on Day 22 during the rest 
period of every cycle, at the End-of Study visit and during maintenance. Also, for 
patients who achieved a CR, very good VGPR, PR, or MR, a sample was 
obtained four weeks following the documentation of initial response for 
confirmation. 
 
Serum Free Light Chain Assay 
 Serum free light chain assays with FLC ratios were conducted during the 
Screening period, on Day 22 of every treatment cycle, at the End-of-Study visit 
and during the maintenance period. FLC assays were only used to assess 
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patients without measurable serum and urine M-protein levels.  
 
Bone Marrow Aspirate and Biopsy 
 Bone marrow aspirates and biopsies were collected during the Screening 
period and for patients who achieved a CR by immunofixation on two 
consecutive assessments. Patients with MM have malignant monoclonal plasma 
cell infiltration of the bone marrow. Bone marrow samples were evaluated to 
calculate the percentage of these cells present in the marrow.  
 
Beta-2 Microglobulin (β2-M) 
 β2-M was assayed from serum during the Screening period, on Day 22 of 
each cycle, at the End-of-Study visit and during maintenance therapy. Serum β2-
M is a prognostic factor for OS for MM patients. A higher amount of this protein 
which forms part of the MHC-I structure is correlated with a poor prognosis.  
 
Skeletal Survey 
 During the Screening period, a retrogenographic skeletal survey of bones 
including humeri and femora were taken to look for bone abnormalities, such as 
lytic lesions. Skeletal surveys were also conducted on patients who develop new 





 The inclusion and exclusion criteria as stated in the Oncotherapeutics 
study protocol can be found in Appendix D. 
 
Final Statistical and Quantitative Analyses 
 Continuous variables were summarized using descriptive statistics and 
categorical variables were summarized using frequencies and percentages. Data 
evaluated included age, gender, and race. The ORR, defined as the sum of 
patients who achieve a CR, VGPR, or PR, and clinical benefit rate CBR defined 
as the ORR plus the number of patients who achieve a MR, was estimated 
based on all subjects who completed at least once cycle of therapy. PFS, DOR, 
and OS were estimated based on the Kaplan-Meier statistical analysis method.  
 
Efficacy Analysis  
 Efficacy was only evaluated for patients who completed at least one cycle 
of treatment. The primary efficacy variables were the ORR and the CBR which 
were calculated based on the patients treated. The secondary efficacy variables 
were: 
 
• TTP, defined as the time from initiation of therapy to PD. 
• PFS, defined as the time from initiation of therapy to PD or death from any 
cause, whichever occurs first. 
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• TTR, defined as the time from the initiation of therapy to the first evidence of a 
confirmed response (CR, VGPR, PR or MR). 
• DOR, defined as the time from first response to PD. 
• OS, defined as the time from initiation of therapy to death from any cause or 
last follow-up visit. 
 
Safety Analysis 
 The safety and tolerability of IXZ as a replacement for BTZ or CFZ in 
combination therapies that contain either of these drugs was primarily 
investigated by the frequency of AEs and SAEs throughout the trial. AEs and 
SAEs were based on the protocol definitions found in Appendix E. In addition, the 
MTD for the three combination therapies for which it is unknown was investigated 






Study Subject Demographics, Previous Regimens, and Enrollment 
  
Of the 47 patients screened for the study, only one failed to meet the 
required criteria. One more patient passed the screening but failed Cycle 1 Day 1 
labs before being dispensed the study drug. As a result, 45 patients received 
drug and therefore were evaluable for safety. Of these 45 patients, only 38 
completed at least one cycle of treatment and therefore were evaluable for 
efficacy. The median age of patients who received drug was 67 and were mostly 
woman (62.2%). In addition, most patients were non-Hispanic white (86.7%).  
Table 2: Demographics and Patient Enrollment Information 
Demographics # of Patients (%) 
Median Age (Range) 67 (45-82) 
Sex (Male, Female) 17, 28 (37.8, 62.2) 
Non-Hispanic White 39 (86.7) 
Black/African American 3 (6.7) 
Hispanic/Latino 3 (6.7) 
Patient Enrollment 
# of Patients Screened 47 
# of Screen Fails 1 
# of Patients Receiving Study Drug 45 
# of Patients Evaluable for Efficacy 38 




 Patients previously treated with ten combination treatments were qualified 
to be included in the study. However, only patients with six of those treatments 
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were ultimately enrolled in the study. Five patients were on combination 
treatments that were not originally qualifying in the protocol but were given 
exempt status because of the similarity to qualifying treatments. These 
combinations were: BTZ + ascorbic acid + melphalan + dexamethasone (1 
patient) and BTZ + dexamethasone + cyclophosphamide + ascorbic acid (4 
patients). 
 
Table 3: Qualifying Combination Regimens Frequency 
Qualifying Combination Regimen # of Patients 
BTZ+ melphalan + prednisone 0 
BTZ + cyclophosphamide + dexamethasone 4 
BTZ + cyclophosphamide + ascorbic acid 5 
BTZ + PLD + dexamethasone 14 
BTZ + dexamethasone 8 
CFZ + dexamethasone 6 
BTZ + lenalidomide + dexamethasone 3 
CFZ + lenalidomide + dexamethasone 0 
BTZ + pomalidomide + dexamethasone 0 
CFZ + pomalidomide + dexamethasone 0 
Other Approved Combination Treatments 5 
 
Safety Results 
Safety was assessed through the monitoring of AEs, SAEs, and MTD 
determination in individuals within the study population. MTD determination 
occurred during the phase 1 portion of the study. Only SAEs and AEs that were 
Grade 3 or above were coded and quantified for analysis:  
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Table 4: ≥ Grade 3 AEs Table 5: ≥ Grade 3 SAEs 
	
   
Adverse Event Grade # of Patients (%) 
Anemia 3 2 (4.4) 
Bilateral Cataracts 3 1 (2.2) 
Bone Pain 3 1 (2.2) 
Colitis 3 1 (2.2) 
Confusion 4 1 (2.2) 
Dehydration 3 1 (2.2) 
Difficulty 
Breathing  3 1 (2.2) 
Dyspnea 3 1 (2.2) 
Episode of 
Hallucination  3 1 (2.2) 
Fatigue 3 1 (2.2) 
Hyponatremia 3 2 (4.4) 
Increased 
Creatinine 3 1 (2.2) 
Leukocytosis Left 
Shift 3 1 (2.2) 
Leukopenia 3 1 (2.2) 
Low Hemoglobin 3 1 (2.2) 
Low Platelets 3 1 (2.2) 
Multiple Seizures  4 1 (2.2) 




3 1 (2.2) 
Severe Lower 
Back Pain  3 1 (2.2) 
Shortness of 
Breath 3 1 (2.2) 
Thrombocytopenia 3 1 (2.2) 
Thrombocytopenia 4 1 (2.2) 
Watershed Infarct 





Acute Kidney Injury  3 1 (2.2) 
Anemia 3 1 (2.2) 
Atrial Fibrillation 3 1 (2.2) 
Back Pain 3 1 (2.2) 
Bone Pain 3 1 (2.2) 
Bronchitis 3 1 (2.2) 
Candida Esophagitis 4 1 (2.2) 
COPD Exacerbation 3 1 (2.2) 
Dehydration 3 1 (2.2) 
Epistaxis 3 1 (2.2) 
Gastroenteritis 3 1 (2.2) 
Generalized Neuritis 3 1 (2.2) 
Hip Fracture 3 1 (2.2) 
Hyponatremia 3 2 (4.4) 
Hypovolemic Shock  4 1 (2.2) 
Liver Mets From 
Unknown Primary 3 1 (2.2) 
MRSA UTI 3 1 (2.2) 
Myocardial Infarct  4 1 (2.2) 
Overdose on Fentanyl 
Patch 3 1 (2.2) 
Pancytopenia 3 1 (2.2) 
Perineal Abscess 3 1 (2.2) 
Pneumonia 3 2 (4.4) 
Respiratory Failure  5 1 (2.2) 
Sepsis 4 1 (2.2) 
Shortness of Breath 3 1 (2.2) 
Spinal Mets 3 1 (2.2) 
Syncope 3 1 (2.2) 
Urinary Tract Infection 3 1 (2.2) 
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During the study, 24 different AEs were reported that were above and 
including Grade 3. All occurred in only 2.2% of patients, except for anemia and 
hyponatremia which both occurred in 4.4% of patients. Although it is required to 
report all AEs that occur during the study, relation to IXZ is assessed by 
physicians during clinic visits. Of all AEs that occurred, only the single 
occurrences of hallucination, thrombocytopenia (Grade 4), and neutropenia were 
categorized as “possibly related” to IXZ. The single occurrences of 
thrombocytopenia (Grade 3), leukopenia, confusion, difficulty breathing, multiple 
seizures, stroke, severe lower back pain, and low hemoglobin were categorized 
as “probably related” to IXZ. With regards to SAEs, all 28 occurred in 2.2% of 
patients except pneumonia and hyponatremia, both of which occurred in 4.4% of 
patients. Also, only single occurrences of generalized neuritis, gastroenteritis, 
myocardial infarction, and respiratory failure were categorized as “probably 
related”.  
The three combination regimens requiring MTD determination all had 
patients participating in the phase 1 portion of the study. The other seven 
combinations have had MTD previously determined at 4 mg and proceeded 
directly to phase 2 using this dose. Two DLTs caused two dose reductions in the 
BTZ+PLD+ dexamethasone cohort. Most patients on the study were previously 
on this combination treatment. However, due to a small sample size and 
similarity in frequency of dose levels, MTD was not definitively determined for all 
three combination treatments.  
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# of Pats on 
Regimen 
# of Pats 
@ 4mg 
# of Pats @ 3 
mg 
# of Pats @ 
2.3mg 
BTZ + PLD + 
Dex 14 6 
7(1 Dose 
reduction from 4 
mg) 
1 (1 Dose 





4 2 2 0 
BTZ + Ascorbic 
Acid + 
Cyclophos 
5 3 2 0 
Total 23       
 
Efficacy Results 
 Efficacy was investigated by determining ORR and CBR. In addition, 
42.1% of patients did not respond to the treatment at all, having PD as their best 
response. The second most frequent best response was SD, occurring in 39.5% 
of patients: 






CR 0 0 
VGPR 0 0 
PR 5 13.2 
MR 2 5.3 
SD 15 39.5 




In addition, the following diseases parameters were analyzed to contribute 
to the efficacy results: TTP, PFS, TTR, DOR and OS. Kaplan-Meier statistical 
analysis was used to calculate PFS, DOR, and OS. ORR and CBR were 13.2% 
and 18.4% respectively, while PFS was 2.10 months: 








Response Rates # of Patients % 
ORR (CR+VGPR+PR) 5 13.2 
CBR (CR+VGPR+PR+MR) 7 18.4 
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 During the study, SAEs were experienced by only 24.4% of patients 
enrolled. This low SAE rate suggests that IXZ is a safe replacement for CFZ and 
BTZ in RRMM patients who have progressed on their previous regimen. In a 
study conducted by the drug manufacturer Takeda Pharmaceuticals and sponsor 
Millennium Pharmaceuticals used for FDA approval, 47% of participants that 
were given IXZ instead of a placebo experienced at least one SAE (≥ Grade 3), 
which is significantly more than in the CFZ/BTZ replacement study (Moreau et 
al., 2016). The Takeda study compared IXZ + lenalidomide + dexamethasone vs. 
placebo + lenalidomide + dexamethasone, which is one of the combination 
therapies investigated in the CFZ/BTZ replacement study.  
Of the three patients in the CFZ/BTZ replacement study who underwent 
the IXZ + lenalidomide + dexamethasone combination treatment, all patients 
experienced at least one SAE, which was a significantly higher rate than the 
other combination regimens studied. It is possible that this particular combination 
regimen causes a higher rate of SAEs, making their occurrence higher in the 
Takeda study since it only investigated that regimen. The diversity in combination 
treatments investigated in the CFZ/BTZ replacement study may account for the 
discrepancy between the overall SAE rates between the two studies. In addition, 
the significantly larger sample sizes and geographic diversity of subjects in the 
international Takeda study most likely partially accounts for the differences 
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between the results.  
 Another study investigating IXZ reported thrombocytopenia and 
neutropenia as AEs attributed to specifically to IXZ (Moreau, 2014). This finding 
suggests that although IXZ is relatively safe compound compared to other PIs, 
special attention should be given to monitoring for these particular AEs as they 
seem to be found across different studies, including the CFZ/BTZ replacement 
and Takeda studies. In addition, no patients experienced PN. This finding was 
expected because PN was found to occur infrequently in patients taking IXZ 
according to previously published literature (S. Kumar et al., 2013). In the 
CFZ/BTZ replacement study, 33.3% of patients experienced at least one ≥ Grade 
3 AE in comparison to the Takeda study, which was 74%. It is possible that the 
IXZ + lenalidomide + dexamethasone combination treatment is more prone to 
AEs as well. All three patients that were given this treatment in the CFZ/BTZ 
replacement study reported at least one ≥ Grade 3 AE, which was higher than 
the other regimens investigated. The discrepancy in such results can also be 
attributed to the differences between the number of combination regimens 
chosen, sample size and subject diversity.  
 This study also investigated the MTD for IXZ in three combination 
regimens for which it was previously unknown. Due to the small sample size 
(N=23) and similarity in frequency of individual maximum dose levels, overall 
MTD was not definitively determined for all three combination treatments. 
However, this information could be a useful reference for physicians prescribing 
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IXZ who want to know which dose levels can possibly produce DLTs. Physicians 
may also have to use their own judgement in finding the right dose through 
individual dose escalation. During the study, only two DLTs occurred at different 
IXZ dose levels, both of which were in the BTZ + PLD + dexamethasone cohort. 
It is possible that PLD and dexamethasone, in combination with IXZ, tends to 
potentiate the chances of DLTs occurring. On the other hand, it is worth noting 
that the majority of patients from the MTD determination regimens were in the 
BTZ + PLD + dexamethasone cohort, increasing the likelihood that a DLT would 
occur within this group.  
  
Efficacy 
 As discussed below, this study demonstrated that IXZ is not an efficacious 
replacement for BTZ or CFZ in combination therapies containing either of these 
two drugs. The RRMM patients continued to progress, on average, soon after 
IXZ was introduced with the few responses lasting for only a short period of time. 
This information could be used to provide additional information to physicians 
who are considering placing patients on these regimens. All the efficacy 
endpoints were considerably low, showing that IXZ does not delay MM disease 
progression by much in this context. The primary efficacy variables evaluated in 
the study were ORR and CBR, which were 13.2% and 18.4% respectively. These 
values are significantly lower than the results found in other studies. For 
example, the ORR in the Takeda study was 78% in the IXZ administered group. 
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However, the two patients in the CFZ/BTZ replacement study who completed 
more than one cycle of therapy (thus were qualified to be included in the efficacy 
analysis) and received the same combination therapy as the patients in the 
Takeda Study (IXZ + Lenalidomide + Dexamethasone) had MR as their best 
response. This is significant because only seven patients in the entire CFZ/BTZ 
replacement study responded (≥ MR). It is possible that this particular 
combination has a better efficacy than the others.   
In addition, the PFS between the studies varied significantly (2.1 months 
for the CFZ/BTZ replacement study vs. 20.6 months for the Takeda study), 
further indicating that the CFZ/BTZ replacement patients did not respond as well. 
As a result of the ineffectiveness of this treatment, secondary efficacy variables 
such as the DOR were also low (2.0 months vs. 20.5 months). Overall, it is clear 
that patients had little or short lived change in disease status when compared to 
before IXZ was administered. Appropriately, physicians should consider other 
avenues of treatment for patients who have stopped responding to these prior 
therapies. However, all other variables between studies were similar or were not 
presented in the Takeda study (Moreau et al., 2016). 
Another explanation for the differing results between these studies is that 
only 69% of participants in the Takeda IXZ administered cohort had a previous PI 
containing therapy compared to 100% in the CFZ/BTZ replacement study 
(Moreau et al., 2016). This suggests that 31% of patients in the Takeda study 
were naive to PIs and thus were more susceptible to better responses because 
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of a lack of resistance. Finally, the discrepancy in the results between the two 
studies may be explained by the significant difference in the number of subjects 
(38 vs. 390 given IXZ) and countries where patients were recruited (1 vs. 26 in 
the international Takeda study). Genetics, environmental factors, and other 
demographics that can differ amongst individuals in different countries could 
have had an effect on the results.  
 
Limitations of the Study 
 Although the study was conducted through rigorous and detailed protocol 
procedures, there are some limitations to be considered. First, at the start of the 
study, the enrollment goal was to have a total of 60 participants. Only 45 patients 
actually screened, qualified, and received the study drug IXZ. As a result, the 
study population was smaller than expected, potentially skewing the results. A 
larger population size would have added further strength to the findings. In 
addition, 51.1% of study patients (qualifying for at least the safety analysis) were 
treated in the same clinic and 58.3% of the total clinics were located in California. 
Having the majority of data coming from one source may have created a bias in 
the results. Also, 86.7% of the patients were non-Hispanic white, possibly limiting 
the application of the results to the general public.  
 Finally, the distribution of patients amongst the various combination 
treatments was uneven. For example, 31.1% of total patients qualified for the 
study under the BTZ + PLD + dexamethasone combination treatment while none 
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were in the CFZ + lenalidomide + dexamethasone group. As a result, study 
applicability to the wide array of PI containing regimens that are commonly used 
to treat MM may be limited.  
 
Areas of Future Study 
 Future studies may also include exploring IXZ in the combination 
treatments (BTZ+ melphalan + prednisone, CFZ + lenalidomide + 
dexamethasone, BTZ + pomalidomide + dexamethasone, CFZ + pomalidomide + 
dexamethasone) that did not enroll patients during this study.  Although replacing 
the PIs in some of the combination regimens listed would result in the same 
experimental regimen (IXZ + pomalidomide + dexamethasone), it is of interest to 
see how patients who have been exposed to different PIs in the past respond to 
IXZ.   
 On the other hand, there are numerous other avenues of treatment being 
developed for MM that warrant further investigation through clinical trials. 
Amongst these is the use of novel drugs such as selinexor, which blocks the 
nuclear export protein XPO1. Selinexor is orally bioavailable and has shown 
antimyeloma activity regardless of genotype, signaling that it could be used in a 
large patient population. This drug induces apoptosis in cancerous cells by 
blocking the export of nuclear proteins into the cytoplasm. These proteins are 
involved in cancer cell growth and their blockage eventually arrests the cell cycle, 
causing cell death. When XPO1 is overexpressed, survival outcome in patients is 
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poor and disease states progress. Fortunately, the effects of selinexor are 
selectively lethal to myeloma cells and seem to have minimal effect on normal 
cells. This is the first MM drug that uses this novel mechanism of action (Vogl et 
al., 2018).  
 Another next-generation MM drug is elotuzumab, a humanized IgG 
monoclonal antibody designed to fight MM. Antibodies have recently been 
explored with increasing interest because of their ability to use the immune 
system as a method to kill MM cells and solid tumors. They have the potential to 
overcome the resistance associated with other drugs in high-risk patients 
regardless of the MM cells’ biological characteristics or cytogenetics. Elotuzumab 
targets the transmembrane Signaling Lymphocyte Activation Molecule family of 
proteins that are present on the surface of MM plasma cells. As a result, the drug 
has a dual mechanism of action: it causes direct activation of natural killer cells 
while also causing antibody-dependent cellular cytotoxicity of MM cells (Ritchie & 
Colonna, 2018). Future studies should investigate how these drugs affect MM 
disease progression in combination with therapies that are already widely used, 






Appendix A: Complete IMWG Response Criteria 
 




Complete response as defined below plus normal FLC ratio** and 
absence of clonal cells in bone marrow biopsy by 
immunohistochemistry (κ/λ ratio ≤4:1 or ≥1:2 for κ and λ patients, 
respectively, after counting ≥100 plasma cells)†† 
Complete 
response 
Negative immunofixation on the serum and urine and disappearance 




Serum and urine M-protein detectable by immunofixation but not on 
electrophoresis or ≥90% reduction in serum M-protein plus urine M-
protein level <100 mg per 24 h 
Partial response ≥50% reduction of serum M-protein plus reduction in 24 h urinary M-
protein by ≥90% or to <200 mg per 24 h; 
If the serum and urine M-protein are unmeasurable, a ≥50% 
decrease in the difference between involved and uninvolved FLC 
levels is required in place of the M-protein criteria; 
If serum and urine M-protein are unmeasurable, and serum-free light 
assay is also unmeasurable, ≥50% reduction in plasma cells is 
required in place of M-protein, provided baseline bone marrow 
plasma-cell percentage was ≥30%. In addition to these criteria, if 
present at baseline, a ≥50% reduction in the size (SPD)§§ of soft 
tissue plasmacytomas is also required 
Minimal 
response 
≥25% but ≤49% reduction of serum M-protein and reduction in 24-h 
urine M-protein by 50–89%. In addition to the above listed criteria, if 
present at baseline, a ≥50% reduction in the size (SPD)§§ of soft 
tissue plasmacytomas is also required 
Stable disease Not recommended for use as an indicator of response; stability of 
disease is best described by providing the time-to-progression 
estimates. Not meeting criteria for complete response, very good 
partial response, partial response, minimal response, or progressive 
disease 
Standard IMWG response criteria ǁ 
Progressive 
disease ¶¶, ǁǁ 
Any one or more of the following criteria: 
Increase of 25% from lowest confirmed response value in one or 
more of the following criteria: 
Serum M-protein (absolute increase must be ≥0·5 g/dL); 




Urine M-protein (absolute increase must be ≥200 mg/24 h); 
In patients without measurable serum and urine M-protein levels, the 
difference between involved and uninvolved FLC levels (absolute 
increase must be >10 mg/dL); 
In patients without measurable serum and urine M-protein levels and 
without measurable involved FLC levels, bone marrow plasma-cell 
percentage irrespective of baseline status (absolute increase must 
be ≥10%); 
Appearance of a new lesion(s), ≥50% increase from nadir in SPD§§ 
of >1 lesion, or ≥50% increase in the longest diameter of a previous 
lesion >1 cm in short axis; 
≥50% increase in circulating plasma cells (minimum of 200 cells per 
μL) if this is the only measure of disease 
Clinical relapse Clinical relapse requires one or more of the following criteria: 
Direct indicators of increasing disease and/or end organ dysfunction 
(CRAB features) related to the underlying clonal plasma-cell 
proliferative disorder. It is not used in calculation of time to 
progression or progression-free survival but is listed as something 
that can be reported optionally or for use in clinical practice; 
Development of new soft tissue plasmacytomas or bone lesions 
(osteoporotic fractures do not constitute progression); 
Definite increase in the size of existing plasmacytomas or bone 
lesions. A definite increase is defined as a 50% (and ≥1 cm) 
increase as measured serially by the SPD§§ of the measurable 
lesion; 
Hypercalcemia (>11 mg/dL); 
Decrease in haemoglobin of ≥2 g/dL not related to therapy or other 
non-myeloma-related conditions; 
Rise in serum creatinine by 2 mg/dL or more from the start of the 
therapy and attributable to myeloma; 
Hyperviscosity related to serum paraprotein 
Relapse from 
complete 
response (to be 
used only if the 
end point is  
disease-free 
survival) 
Any one or more of the following criteria: 
Reappearance of serum or urine M-protein by immunofixation or 
electrophoresis; 
Development of ≥5% plasma cells in the bone marrow; 
Appearance of any other sign of progression (i.e., new 
plasmacytoma, lytic bone lesion, or hypercalcemia see above) 
For MRD assessment, the first bone marrow aspirate should be sent to MRD (not for 
morphology) and this sample should be taken in one draw with a volume of minimally 2 
mL (to obtain sufficient cells), but maximally 4–5 mL to avoid hemodilution. 
IMWG=International Myeloma Working Group. MRD=minimal residual disease. 
NGF=next-generation flow. NGS=next-generation sequencing. FLC=free light chain. M-
protein=myeloma protein. SPD=sum of the products of the maximal perpendicular 
diameters of measured lesions. CRAB features=calcium elevation, renal failure, 
anemia, lytic bone lesions. 
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FCM=flow cytometry. SUVmax=maximum standardized uptake value. 
MFC=multiparameter flow cytometry. 18F-FDG PET=18F-fluorodeoxyglucose PET. 
ASCT=autologous stem cell transplantation. 
* All response categories require two consecutive assessments made any time before 
starting any new therapy; for MRD there is no need for two consecutive 
assessments, but information on MRD after each treatment stage is recommended 
(e.g., after induction, high-dose therapy/ASCT, consolidation, maintenance). MRD 
tests should be initiated only at the time of suspected complete response. All 
categories of response and MRD require no known evidence of progressive or new 
bone lesions if radiographic studies were performed. However, radiographic studies 
are not required to satisfy these response requirements except for the requirement 
of FDG PET if imaging MRD-negative status is reported. 
† Sustained MRD negativity when reported should also annotate the method used 
(e.g., sustained flow MRD-negative, sustained sequencing MRD-negative). 
‡ Bone marrow MFC should follow NGF guidelines. The reference NGF method is an 
eight-color two-tube approach, which has been extensively validated. The two-tube 
approach improves reliability, consistency, and sensitivity because of the acquisition 
of a greater number of cells. The eight-color technology is widely available globally 
and the NGF method has already been adopted in many flow laboratories 
worldwide. The complete eight-color method is most efficient using a lyophilized 
mixture of antibodies which reduces errors, time, and costs. 5 million cells should be 
assessed. The FCM method employed should have a sensitivity of detection of at 
least 1 in 105 plasma cells.  
§ DNA sequencing assay on bone marrow aspirate should use a validated assay such 
as LymphoSIGHT (Sequenta).  
¶ Criteria used by Zamagni and colleagues, and expert panel (IMPetUs; Italian 
Myeloma criteria for PET Use).   Baseline positive lesions were identified by 
presence of focal areas of increased uptake within bones, with or without any 
underlying lesion identified by CT and present on at least two consecutive slices. 
Alternatively, a  SUVmax=2·5 within osteolytic CT areas >1 cm in size, or SUVmax=1·5 
within osteolytic CT areas ≤1 cm in size were considered positive. Imaging should be 
performed once MRD negativity is determined by MFC or NGS. 
ǁ Derived from international uniform response criteria for multiple myeloma. Minor 
response definition and clarifications derived from Rajkumar and colleagues When 
the only method to measure disease is by serum FLC levels: complete response can 
be defined as a normal FLC ratio of 0.26 to 1.65 in addition to the complete 
response criteria listed previously. Very good partial response in such patients 
requires a ≥90% decrease in the difference between involved and uninvolved FLC 
levels. All response categories require two consecutive assessments made at any 
time before the institution of any new therapy; all categories also require no known 
evidence of progressive or new bone lesions or extramedullary plasmacytomas if 
radiographic studies were performed. Radiographic studies are not required to 
satisfy these response requirements. Bone marrow assessments do not need to be 
confirmed. Each category, except for stable disease, will be considered unconfirmed 
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until the confirmatory test is performed. The date of the initial test is considered as 
the date of response for evaluation of time dependent outcomes such as duration of 
response. 
** All recommendations regarding clinical uses relating to serum FLC levels or FLC ratio 
are based on results obtained with the validated Freelite test (Binding Site, 
Birmingham, UK). 
††Presence/absence of clonal cells on immunohistochemistry is based upon the κ/λ/L 
ratio. An abnormal κ/λ ratio by immunohistochemistry requires a minimum of 100 
plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone 
is κ/λ of >4:1 or <1:2. 
‡‡ Special attention should be given to the emergence of a different monoclonal protein 
following treatment, especially in the setting of patients having achieved a 
conventional complete response, often related to oligoclonal reconstitution of the 
immune system. These bands typically disappear over time and in some studies have 
been associated with a better outcome. Also, appearance of monoclonal IgG κ in 
patients receiving monoclonal antibodies should be differentiated from the therapeutic 
antibody. 
§§ Plasmacytoma measurements should be taken from the CT portion of the PET/CT, or 
MRI scans, or dedicated CT scans where applicable. For patients with only skin 
involvement, skin lesions should be measured with a ruler. Measurement of tumor 






Appendix B: Dose Limiting Toxicities  
Non-hematologic:  
• ≥ Grade 3 non-hematological toxicity (excluding nausea, vomiting, diarrhea, fatigue 
lasting < 14 days, increased serum creatinine or electrolyte abnormalities that are 
not clinically significant and require no treatment)  
• ≥ 2× increase in serum creatinine from baseline lasting ≥ 72 hours  
• ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic 
/antidiarrheal therapy  
 
Hematologic:  
• Grade 4 neutropenia (ANC < 500/mm3) lasting for > 7 days  
• Febrile neutropenia (ANC < 1000/mm3 with a fever ≥ 38.3ºC) of any duration  
• Grade 4 thrombocytopenia (< 25,000/mm3) that persists for > 14 days, despite 
holding treatment  










The NCI Common 
Terminology Criteria for 
Adverse Events is a 
descriptive terminology 
which can be utilized for 
Adverse Event (AE) 
reporting. A grading 
(severity) scale is provided 





SOC System Organ Class, 
the highest level of the 
MedDRA hierarchy, is 
identified by anatomical or 
physiological system, 
etiology, or purpose (e.g., 
SOC Investigations for 
laboratory test results). 
CTCAE terms are grouped 
by MedDRA Primary 
SOCs. Within each SOC, 
AEs are listed and 
accompanied by 





An Adverse Event (AE) is 
any unfavorable and 
unintended sign (including 
an abnormal laboratory 
finding), symptom, or 
disease temporally 
associated with the use of 
a medical treatment or 
procedure that may or may 
not be considered related 
to the medical treatment or 




A brief definition is 
provided to clarify the 




 Grade refers to the 
severity of the AE. The 
CTCAE displays Grades 1 
through 5 with unique 
clinical descriptions of 
severity for each AE based 
on this general guideline: 
 
 Grade 1- Mild; 
asymptomatic or mild 
symptoms; clinical or 
diagnostic observations 
only; intervention not 
indicated.  
 
Grade 2- Moderate; 






 Grade 3- Severe or 
medically significant but 
not immediately life-
threatening; hospitalization 
or prolongation of 
hospitalization indicated; 
disabling; limiting self care 
ADL**.  
 
Grade 4- Life threatening 
consequences; urgent 
intervention indicated.  
 
Grade 5- Death related to 
AE. 
 
Not all Grades are 
appropriate for all AEs. 
Therefore, some AEs are 
listed with fewer than five 





Grade 5 (Death) is not 
appropriate for some AEs 
and therefore is not an 
option.  
 
Activities of Daily Living 
(ADL) *Instrumental ADL 
refer to preparing meals, 
shopping for groceries or 




 **Self care ADL refer to 
bathing, dressing and 
undressing, feeding self, 
using the toilet, taking 




that is a unique 
representation of a specific 
event used for medical 
documentation and 
scientific analyses. Each 
CTCAE v4.0 term is a 
MedDRA LLT (Lowest 
Level Term). 
 
 A Semi-colon indicates ‘or’ 
within the description of the 
grade. A single dash (-) 






Appendix D: Oncotherapeutics Study Protocol Inclusion and Exclusion Criteria 
Each patient must meet all of the following inclusion criteria to be enrolled in the study:  
1. Male or female patients 18 years or older.  
2. Patients must meet the following clinical laboratory criteria:  
a. Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 50,000/mm3. If 
the bone marrow is extensively infiltrated (> 70% plasma cells) then ANC ≥ 1.0 x 
109/L and platelet count ≥ 50.0 X 109/L.  
b. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 
days prior to study enrollment.  
c. Hemoglobin > 8 g/dL. Use of erythropoietic stimulating factors and red blood cell 
(RBC) transfusions per institutional guidelines is allowed; however, most recent RBC 
transfusion must have been at least 7 days prior to obtaining screening hemoglobin.  
d. Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN).  
e. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.  
f. Calculated creatinine clearance ≥ 30 mL/min. Calculation are based on a standard 
formula, as the Cockcroft and Gault (see Appendix 1).  
g. AST (SGOT) and ALT (SGPT) ≤ 3 x ULN or ≤ 5 x ULN, respectively if hepatic 
metastases are present.  
h. LVEF ≥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of 
evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not 
available.  
3. Patients have a life-expectancy ≥ than 6 months  
4. Patients must have a diagnosis of MM, based on standard criteria2 as follows:  
 
Major criteria:  
1. plasmacytomas on tissue biopsy  
2. bone marrow plasmacytosis (greater than 30% plasma cells)  
3. monoclonal immunoglobulin spike on serum electrophoresis IgG greater than 3.5 g/dL or IgA 
greater than 2.0 g/dL; kappa or lambda light chain excretion greater than 1 g/day on 24-hour 
urine protein electrophoresis  
 
Minor criteria:  
1. bone marrow plasmacytosis (10% to 30% plasma cells)  
2. monoclonal immunoglobulin present but of lesser magnitude than given under major criteria  
3. lytic bone lesions  
4. normal IgM less than 50 mg/dL, IgA less than 100 mg/dL, or IgG less than 600 mg/dL  
 
Any of the following sets of criteria will confirm the diagnosis of multiple myeloma:  
a. any 2 of the major criteria  
b. major criterion 1 plus minor criterion 2, 3, or 4  
c. major criterion 3 plus minor criterion 1 or 3  
d. minor criteria 1, 2, and 3, or 1, 2, and 4  
 
5. Currently has MM with measurable disease, defined as:  
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a. a monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 g/dL 
and/or  
b. urine monoclonal protein levels of at least 200 mg/24 hours  
c. for patients without measurable serum and urine M-protein levels, an abnormal 
serum free light chain ratio (normal value: 0.26 – 1.65) or abnormal serum free light 
chain of > 100 mg/L  
6. Currently has progressive MM and has progressed while receiving or within 8 weeks of 
receiving bortezomib or carfilzomib as part of a combination treatment. MM patients that 
demonstrate refractory disease, as defined below, are also eligible for enrollment provided they 
fulfill the other eligibility criteria:  
a. Patients are refractory to a bortezomib or carfilzomib combination regimen, when 
they progress while currently receiving a bortezomib or carfilzomib combination 
treatment, or within 8 weeks of its last dose. Patients are considered relapsed, when 
they progress between 8 and 12-weeks from their last dose of bortezomib or 
carfilzomib as part of a bortezomib- or carfilzomib-combination therapy. Prior treatment 
with four days or less of a total of 400 mg of prednisone (or an equivalent potency of 
another steroid) for MM will not be considered a regimen.  
 
7. Patients that were on bortezomib-containing regimens must have been administered at least 
4 doses of a minimum of 1.0 mg/m2 in not more than 28-days cycles. Subjects must have 
received at least one cycle meeting this definition and have shown PD to be considered 
eligible.  
 
8. Patients that were on carfilzomib-containing regimens must have received at least 6 doses 
of 27 mg/m2 in no more than 28 days per cycle. Subjects must have received at least one 
cycle meeting this definition and have shown PD to be considered eligible.  
9. Progressed from one of the specific bortezomib- or carfilzomib-containing regimen as listed 
on Table 5. Although bortezomib- and carfilzomib-containing combination regimens that are 
otherwise identical except for the PI resulting in the same ixazomib regimen, they will be 
enrolled separately so that safety/efficacy can be separately determined, thereby allowing 
comparisons based on the prior PI that subjects were exposed to as part of the regimen that 
they failed (carfilzomib vs. bortezomib).  
10. Patient may have received a carfilzomib- or bortezomib-containing regimen at any time and 
may have received other non-PI-containing intervening treatments.  
11. Patient is able to adhere to the study visit schedule and other protocol requirements  
12. Patient Eastern Cooperative Oncology Group (ECOG) performance status is ≤ 2.  
13. Patients must voluntarily give written consent before any study related procedure not part 
of standard medical care is performed, with the understanding that consent may be withdrawn 
by the patient at any time without prejudice to future medical care.  
14. Female patients:  
a. Who are postmenopausal for at least 1 year before the screening visit, OR  
b. Who are surgically sterile, OR  
c. Of childbearing potential (FCBP). FCBPs must agree to practice two effective 
methods of contraception, at the same time, from the time of signing the informed 
consent form through 90 days after the last dose of study drug, AND  
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d. Must adhere to the guidelines of any treatment-specific pregnancy prevention 
program, OR  
e. Agree to practice true abstinence when this is in line with the preferred and usual 
lifestyle of the subject. Periodic abstinence [e.g., calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception.  
15. Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one 
of the following:  
 
a. To practice effective barrier contraception during the entire study treatment period 
and through 90 days after the last dose of study drug, OR  
b. To adhere to the guidelines of any treatment-specific pregnancy prevention 
program, if applicable, OR  
c. To practice true abstinence when this is in line with the preferred and usual lifestyle 
of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods] and withdrawal are not acceptable methods of contraception.  
 
Exclusion Criteria 5.2 
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:  
1. Female patients who are lactating or have a positive serum pregnancy test during the 
screening period.  
2. Failure to have fully recovered (i.e., ≤ Grade 1 toxicity) from the reversible effects of prior 
chemotherapy.  
3. Major surgery within 14 days before enrollment.  
4. Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days will be 
considered a sufficient interval between treatment and administration of the ixazomib. Receipt 
of localized radiation therapy does not preclude enrollment.  
5. Central nervous system involvement.  
6. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before 
study enrollment.  
7. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled 
hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, NYHA 
Class III or IV heart failure, unstable angina, clinically significant pericardial disease or 
myocardial infarction within the past 6 months, unless subject has a pacemaker. Prior to study 
entry, any ECG abnormality at Screening has to be documented by the investigator as not 
medically relevant.  
8. Systemic treatment, within 14 days before the first dose of ixazomib, or current treatment 
with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of 
CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, 
posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, 
phenytoin, phenobarbital), or use of Ginkgo biloba or St. John’s wort.  
 
9. Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human 
immunodeficiency virus (HIV) positive status.  
10. Any serious medical or psychiatric illness that could, in the investigator’s opinion, 
potentially interfere with the completion of treatment according to this protocol.  
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11. Known allergy to any of the study medications, their analogues, or excipients in the various 
formulations of any agent.  
12. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance 
of ixazomib including difficulty swallowing.  
13. Diagnosed or treated for another malignancy within 3 years before study enrollment or 
previously diagnosed with another malignancy and have any evidence of residual disease. 
Patients with non-melanomatous skin cancer or carcinoma in situ of any type are not excluded 
if they have undergone complete resection.  
14. Patient has ≥ Grade 3 peripheral neuropathy or Grade 2 with pain during the screening 
period.  
15. Participation in other clinical trials, including those with other investigational agents not 
included in this trial, within 21days of the start of this trial and throughout the duration of this 
trial.  
16. Patient has been diagnosed with:  
a. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, 
monoclonal protein (M-protein) and skin changes (POEMS) syndrome.3  
b. Primary amyloidosis  
c. Plasma cell leukemia.  
d. Severe hypercalcemia, i.e., serum calcium = 12 mg/dL (3.0 mmol/L) corrected for 
albumin.  
17. Patient has received the following prior therapy:  
a. Chemotherapy within 28 days of enrollment (6 weeks for nitrosoureas).  
b. Corticosteroids (>10 mg/day prednisone, >8 mg/day methylprednisolone, >2 mg/day 
dexamethasone, or other equivalents) within 21 days of enrollment.  
 
c. Immunotherapy or antibody therapy as well as thalidomide, lenalidomide, 








Appendix E: AE and SAE Definitions 
	
Adverse Event Definition  
AE means any untoward medical occurrence in a patient or subject administered a 
pharmaceutical product; the untoward medical occurrence does not necessarily have a 
causal relationship with this treatment. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product whether or not it 
is related to the medicinal product. This includes any newly occurring event, or a previous 
condition that has increased in severity or frequency since the administration of study 
drug. An abnormal laboratory value will not be assessed as an AE unless that value leads 
to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is 
considered by the investigator to be a clinically significant change from baseline. 
 
Serious Adverse Event Definition  
SAE means any untoward medical occurrence that at any dose:  
• Results in death.  
• Is life-threatening (refers to an AE in which the patient was at risk of death at the time of 
the event. It does not refer to an event which hypothetically might have caused death if it 
were more severe).  
• Requires inpatient hospitalization or prolongation of an existing hospitalization (see 
clarification in the paragraph below on planned hospitalizations).  
• Results in persistent or significant disability or incapacity. (Disability is defined as a 
substantial disruption of a person’s ability to conduct normal life functions).  
• Is a congenital anomaly/birth defect.  
• Is a medically important event. This refers to an AE that may not result in death, be 
immediately life threatening, or require hospitalization, but may be considered serious 
when, based on appropriate medical judgment, may jeopardize the patient, require 
medical or surgical intervention to prevent 1 of the outcomes listed above, or involves 
suspected transmission via a medicinal product of an infectious agent. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse; any organism, 
virus, or infectious particle (e.g., prion protein transmitting Transmissible Spongiform 
Encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.  
 
A distinction should be made between a SAE and an AE that is considered severe in 
intensity (Grade 3 or 4), because the terms serious and severe are NOT synonymous. The 
general term severe is often used to describe the intensity (severity) of a specific event; 
the event itself, however, may be of relatively minor medical significance (such as a Grade 
3 headache). This is NOT the same as the term serious, which describes a patient/event 
outcome or action criteria described above, and is usually associated with events that 
pose a threat to a patient’s life or ability to function. A severe AE (Grade 3 or 4) does not 
necessarily need to be considered serious. For example, a white blood cell count of 
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1000/mm3 to less than 2000 is considered Grade 3 (severe) but may not be considered 




* Retrieved from “A phase 1/2 study of ixazomib as a replacement for bortezomib 
or carfilzomib for multiple myeloma patients recently relapsed or refractory to 
their last combination regimen containing either bortezomib or carfilzomib” study 
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